Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, 03080, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea.
Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
Biomaterials. 2016 Dec;109:23-31. doi: 10.1016/j.biomaterials.2016.09.008. Epub 2016 Sep 13.
Nanoparticles adsorb biomolecules to form corona upon entering the biological environment. In this study, tissue-specific corona formation is provided as a way of controlling protein interaction with nanoparticles in vivo. In the vitreous, the composition of the corona was determined by the electrostatic and hydrophobic properties of the associated proteins, regardless of the material (gold and silica) or size (20- and 100-nm diameter) of the nanoparticles. To control protein adsorption, we pre-incubate 20-nm gold nanoparticles with 5 selectively enriched proteins from the corona, formed in the vitreous, to produce nanoparticle-protein complexes. Compared to bare nanoparticles, nanoparticle-protein complexes demonstrate improved binding to vascular endothelial growth factor (VEGF) in the vitreous. Furthermore, nanoparticle-protein complexes retain in vitro anti-angiogenic properties of bare nanoparticles. In particular, priming the nanoparticles (gold and silica) with tissue-specific corona proteins allows nanoparticle-protein complexes to exert better in vivo therapeutic effects by higher binding to VEGF than bare nanoparticles. These results suggest that controlled corona formation that mimics in vivo processes may be useful in the therapeutic use of nanomaterials in local environment.
纳米粒子进入生物环境后会吸附生物分子形成冠。在这项研究中,组织特异性的冠形成被认为是控制纳米粒子在体内与蛋白质相互作用的一种方法。在玻璃体中,冠的组成取决于相关蛋白质的静电和疏水性特性,而与纳米粒子的材料(金和硅)或尺寸(20nm 和 100nm 直径)无关。为了控制蛋白质的吸附,我们将 20nm 金纳米粒子与在玻璃体中形成的 5 种选择性富集的蛋白质预先孵育,以产生纳米粒子-蛋白质复合物。与裸纳米粒子相比,纳米粒子-蛋白质复合物在玻璃体中与血管内皮生长因子(VEGF)的结合能力得到了提高。此外,纳米粒子-蛋白质复合物保留了裸纳米粒子的体外抗血管生成特性。特别是,用组织特异性的冠蛋白对纳米粒子(金和硅)进行预处理,使得纳米粒子-蛋白质复合物通过与 VEGF 的结合比裸纳米粒子更好,从而在体内发挥更好的治疗效果。这些结果表明,模拟体内过程的可控冠形成可能有助于纳米材料在局部环境中的治疗应用。
Biomaterials. 2016-9-13
Adv Exp Med Biol. 2018
ACS Appl Mater Interfaces. 2020-10-28
Semin Immunol. 2017-10-21
Colloids Surf B Biointerfaces. 2017-4-1
Adv Drug Deliv Rev. 2023-1
Mater Today Bio. 2022-11-11
Adv Sci (Weinh). 2022-5
Adv Exp Med Biol. 2020
Pharmaceutics. 2020-8-12